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Fabry disease, an X-linked lysosomal storage disorder, results from deﬁcient activity of the enzyme α-galactosidase A. Aﬀected
males with the classic phoenotype have acroparaesthesias, hypohidrosis, and corneal opacities in childhood and develop renal
failure, cardiac hypertrophy or strokes in the third to ﬁfth decade of life. Some female heterozygotes are asymptomatic, some as
severely aﬀected as males. The natural history of Fabry patients includes transitory cerebral ischaemia and strokes, even in very
young persons of both genders. The mechanism is partly due to vascular endothelial accumulation of GL-3. White matter lesions
on MRI occur. Both males and females can be safely treated with enzyme replacement; and thus screening for Fabry disease of
young stroke populations should be considered. There are, however, no hard data of treatment eﬀect on mortality and morbidity.
The analyses of results from ongoing studirs will add to the decision on whether or not to screen young stroke patients for Fabry
disease. Finally, stroke prophylactic therapy should be used liberally in patients of both genders with veriﬁed Fabry disease. This
includes primary prevention such as lifestyle counseling, targeting blood pressure, managing atrial ﬁbrillation, diabetes mellitus,
hyperlipidaemia, and ASA.
1.Introduction
Fabry disease is a rare X-linked inborn error of glycosph-
ingolipid metabolism resulting from reduced production of
lysosomal (α-galactosidase A (α-Gal A)) [1]. The enzymatic
deﬁciency leads to lysosomal accumulation of glycosph-
ingolipids, primarily globotriaosylceramide (GL-3), partic-
ularly in vascular endothelial cells throughout the body.
Aﬀected males and symptomatic heterozygous females with
the classical phenotype have manifestations in childhood
or adolescence including angiokeratoma, acroparesthesia,
gastrointestinal manifestations, and corneal opacities. With
advancing age, the progressive vascular involvement results
in renal insuﬃciency, cardiac disease, and strokes [1].
Patients with Fabry disease have a shortened life expectancy
due to the development of a speciﬁc vasculopathy. Male
patients typically develop renal impairment in their third
or fourth decade of life, as well as cardiac hypertrophy
and conduction abnormalities. Life expectancy is reduced
with a median life expectancy between 50 and 57 years for
t h em a l ep o p u l a t i o n[ 2–4]. In females, the disease is more
variable, with less involvement of the kidneys, butlife span is
shortened as well [2, 3, 5]. In female patients, cardiac disease
andcerebralwhitematterlesionsdominateandcontributeto
morbidity and mortality.
Stroke is a common and serious clinical manifestation
of Fabry disease. Recent evidence, from papers on natural
history of Fabry and postmarketing surveillance databases
of Fabry patients treated with enzyme replacement therapy,
has indicated that stroke may appear even in young patients
[6, 7], and stroke has been seen in some patients as the ﬁrst
disease event [7]. Although patients with Fabry disease are
known to experience transient ischaemic attacks (TIAs) and
strokes at an early age [8, 9], there are few quantitativemark-
ers of disease burden in the central nervous system. Fabry
patientsfrequentlyexhibitwhitematterlesions, whichcanbe
detected by conventional neuroimaging methods (reviewed
in [10]). Recently, magnetic resonance diﬀusion tensor
imaging has been used to quantify these abnormalities [11].
However, the risk of clinical cerebrovascular manifestations,
such as stroke and TIAs, is diﬃcult to predict. Thus, because
of the various ways by which diﬀerent studies deﬁned cere-
brovascular complications, the stroke incidence and median
age at ﬁrst stroke cannot be readily compared across studies.2 Stroke Research and Treatment
The approval of r-hα-GAL-A treatment has subsequently
put a pressure on both clinicians and authorities to begin
therapy in aﬀected individuals, and therefore a number of
questions may never be answered by randomized placebo-
controlled trials. Consequently, the only realistic possible
sources to obtain future long-term data is to rely on the
postmarketing surveillance databases run by the pharma-
ceutical companies who market the enzyme products, that
is, Fabry Outcomes Survey (Shire Inc) and Fabry Registry
(Genzyme Inc). The Fabry Registry provides information
on the worldwide largest cohort of patients with Fabry
disease. Both databases are ongoing, observational databases
that track the natural history and outcomes of patients
with Fabry disease. Patient and physician participation is
voluntary. All patients provide informed consent and may
decline to participate or withdraw consent at any time.
The treating physicians determine the actual frequency of
necessary assessments according to a patient’s individualized
need for medical care and routine followup. However,
there is a recommended schedule of assessments for the
enrolled patients. This schedule encompasses assessments
of cerebrovascular and neurological manifestations of the
included patients with Fabry disease.
Although these databases provide only surrogate sources
of information on the clinical outcome of therapy, the level
of evidence is more conclusive than clinical experience with
singular cases, and the two databases have already provided
useful information on the baseline phenotype in women,
information that has not been possible to obtain by other
means in this rare disease [8, 12].
2.Mechanisms forStrokeinPatientswith
Fabry Disease
The understanding of the pathophysiology of the vascu-
lopathy in Fabry disease is limited, as recently reviewed
by Rombach et al. [13]. the removal of glycosphingolipid
from various cell types has been reported in studies inves-
tigating the eﬃcacy of enzyme replacement therapy [14–
17]. However, it has become apparent that the removal
of stored glycosphingolipid from the endothelial cells, as
identiﬁedbyconventionalhistologicalexamination, doesnot
prevent the progression of vascular disease in many patients
[18, 19]. Thus, the traditional concept that prominent
storage in endothelial cells is primarily responsible for the
vascular dysfunction cannot be held. Several investigators
have attempted to unravel the components that contribute
to the general vascular damage. Most studies have been
performed in limited patient populations, usually focusing
on one aspect of the vascular dysfunction rather than on the
complex interplay of all the diﬀerent factors involved.
The mechanisms underlying the stroke pathogenesis
in Fabry disease have thus not been clearly delineated.
Progressive accumulationof GL-3 within the endotheliumof
intracranial blood vessels is thought to play a primary role in
the vasculopathy and risk of ischaemic stroke [20]. However,
other factors such as the presence of a prothrombotic state,
abnormalities in cerebral blood ﬂow velocity, autonomic
dysfunction [21], and increased production of reactive
oxygen species were also identiﬁed as being contributing to
the development of stroke in patients with Fabry disease
[13, 21–24]. Another diﬀerent mechanisms contributing to
the strokes could be emboli or other consequencesof cardiac
arrhythmias [7], that are some of the most important and
common cardiac manifestations in Fabry patients of both
genders [25].
The role of vascular or autonomic dysfunction as a
pathogenic mechanism for stroke in Fabry patients by
compromising cerebral blood ﬂow velocities and cerebral
autoregulation has been elegantly studied by Hilz et al. [21].
They used transcranial Doppler sonography in 22 Fabry
patients and 24 controls and assessed the resistance index,
pulsatility index, cerebrovascular resistance, spectral powers
of oscillations in RR intervals, mean blood pressure, and
mean cerebral blood ﬂow velocities. They hypothesized that
the decreased cerebral blood ﬂow velocities might result
fromdownstreamstenosesofresistancevesselsanddilatation
of the insonated segment of the middle cerebral artery
due to reduced sympathetic tone and vessel wall pathology
with decreased elasticity. Furthermore, the augmented gain
between blood pressure and cerebral blood ﬂow velocities
oscillations indicates an inability to dampen blood pressure
ﬂuctuations by cerebral autoregulation. Thus, both reduced
cerebral blood ﬂow velocitiesand impaired cerebral autoreg-
ulation are likelytobe involvedin theincreased risk ofstroke
in patients with Fabry disease.
The normal function of GL-3 is still a mystery, and the
potential contribution of secondary metabolic phenomena
to the evolution of Fabry disease is unknown [2]. Enzyme
replacement therapy with intravenous infusion of r-hα GAL-
A has been found to consistently decrease GL-3 levels
in plasma and clear lysosomal inclusions from vascular
endothelial cells. Whether this occurs to the same extent
in brain vasculature is unknown. The eﬀects of enzyme
therapy on other tissues are not obvious, and therefore
recommendations for the treatment include commencement
early in the course of the disease in order to be opti-
mally eﬀective in preventing initial or progressive organ
failure and to establish which complications of the disease
that do not respond to intravenously delivered enzyme
[20].
The conclusion from the review by Rombach et al.
[13] was that the smooth muscle cell is the primary cell
involved in the vasculopathy of Fabry disease and that in an
early stage of Fabry vasculopathy, angiotensin II production
becomes upregulated. The proliferation of smooth muscle
cells and GL-3 storage results in a higher intima-media
thickness. Increased reactive oxygen species production as
well as enhanced nitric oxide production may result in
diﬀerent ﬁndings with respect to endothelial activation
markers, which can be severely enhanced in the context of
other vascular risk factors. Selective angiotensin I receptor
blockade may be an interesting option for optimal nitric-
oxide-mediated vasodilatation and should be explored as
adjunctive therapy [13]. Therefore, further studies not only
on both the uptake of α-GAL A in brain vasculature and
tissue, but also on the vasculopathy are needed in order toStroke Research and Treatment 3
optimise the management of the stroke risk and consequent
treatment in patients with Fabry disease.
3.CerebralImaging inFabryDisease Patients
The cerebral involvement in Fabry disease can be visualized
on conventional magnetic resonance imaging (MRI) as
multiple lesions located in the deep white matter and in the
subcortical grey matter of both hemispheres. The cerebral
lesion burden visible on these imaging methods increases
withageandcanprecedetheonsetofneurologicalsymptoms
[26]. Females who are carriers of the disease might show
MRIabnormalitiessimilar tothoseofaﬀectedmales[27,28].
More recent studies, using proton emission tomography
[29] and proton MRI spectroscopy [30], have suggested that
metabolic abnormalities can be found even in the absence
of cerebral lesions in patients with Fabry disease. This was
substantiated [31] in 8 patients (4 males) with Fabry disease
by the use of brain proton MRI/MR spectroscopic imaging
examinations toobtainmeasures oftotalbrainvolumes,total
brain lesion volumes, and magnetization transfer ratios in
white matter and central brain levels of N-acetylaspartate
(NAA) to creatine (Cr). The authors concluded that subtle
structural and metabolic tissue damage could extend beyond
white matter in subjects with Fabry disease. A diﬀuse
decrease in brain NAA/Cr could occur in Fabry subjects
in relation to the degree of their CNS involvement and its
evolution over time.
Moore et al. [32] studied neuroradiologic records of 104
hemizygous patients with Fabry disease for the presence
of hyperintensity on the T1-weighted images. Additional
CT, gradient-echo (T2∗-weighted), and fat-suppression MR
studies were reviewed to characterize further the T1 abnor-
mality in selected patients. Overall, 22 patients (23%)
demonstrated pulvinar hyperintensity on T1-weighted
images; the frequency increased with age to over 30%
by age 50 years. They concluded that hyperintensity in
the pulvinar on T1-weighted images is a common ﬁnding
in Fabry disease, likely reﬂecting the presence of calci-
ﬁcation, and exclusive involvement of the pulvinar may
be distinctively characteristic to Fabry disease. Increased
cerebral blood ﬂow in the posterior circulation, particularly
the thalamus, suggested that the dystrophic calciﬁcation
was secondary to cerebral hyperperfusion and selective
vulnerability of the pulvinar and adjacent thalamic nuclei.
Thus, according to the authors, the ﬁnding of isolated
pulvinar hyperintensity on T1-weighted images should sug-
gest Fabry disease, particularly when seen in conjunction
with othernonspeciﬁc neuroradiologicmanifestations of the
disease.
This ﬁnding was later supported by Burlina et al. [33]
who investigated the pulvinar sign and its relationship
with other clinical ﬁndings in a total of 36 patients (16
males, 20 females) from 14 families. The pulvinar sign was
found in 5 male patients but not in any of the investigated
female patients. Seven patients had had at least one stroke
(territorial or lacunar), butthere was no correlation between
the occurrence of stroke and the pulvinar sign. All patients
with the pulvinar sign had hypertrophic cardiomyopathy.
Four patients out of ﬁve with the pulvinar sign were on
dialysis or had had a kidney transplantation. They suggested
thatthepulvinarsignisahighlyspeciﬁcsignofFabrydisease,
found in male patients with cardiac signs and severe kidney
involvement, and very recently, they also demonstrated the
pulvinar sign in a female Fabry patient (Burlina, personal
communication).
The importance of the pulvinar sign was recently chal-
lenged by Fellgiebel et al. [34], who could not ﬁnd similar
results in a comprehensive study on the diagnostic utility
of diﬀerent MRI and MR angiography measures in Fabry
disease. They investigated 25 clinically aﬀected patients
with Fabry disease (age 36.5 ± 11.0 years) and 20 age-
matched controls by structural MRI, MR angiography,
and diﬀusion tensor imaging. They determined individual
white matter lesion volumes, global mean diﬀusivity, and
mean cerebral artery diameters. Using receiver-operating
characteristic analyses, they were able to demonstrate that
enlarged diameters of the middle cerebral artery, posterior
cerebral artery, carotid artery, and basilar artery signiﬁcantly
separated patients with Fabry disease from controls. A total
of 87% of the individuals were correctly classiﬁed by basilar
arterydiameters(sensitivity95%,speciﬁcity83%),whilenei-
ther white matter lesion volumes nor global mean diﬀusivity
values could signiﬁcantly separate patients from controls.
In their study, basilar artery diameters were superior to all
otherMRmeasuresforseparatingpatientswithFabrydisease
from controls with an accuracy of 87%, and they therefore
recommended that future studies should adopt basilar artery
measurements for early detection and monitoring of brain
involvement in Fabry disease. All in all, the latter could
speak in favour of performing further investigations toreveal
if the dilated vasculopathy in Fabry disease could be a
screening marker to detect Fabry disease in a cohort of other
cerebrovascular diseases, especially in cryptogenic stroke in
young individuals.
4.Prevalence ofStrokein FabryPatients
Severalstudieshave estimated theincidenceofstroke invari-
ouss m a llc oh ortsofpa ti en tswi thF a brydi s ea s e.V eddereta l.
[2] reported that 12 of 25 males (48%) and 13 of 41 females
(32%)had experienced a cerebrovascular accidentor lacunar
stroke,atamedian ageof46and52years, respectively.Gupta
et al. [35] reported that 4 of 54 female Fabry patients (7%)
had experienced strokes, at a median age of 51 years, and
Mehta et al. [26] found that 24 of 216 males (11%) and 27 of
172 females (16%) had experienced either a TIA or a stroke.
Grewal et al. reviewed various types of imaging data and
reported that 8 of 33 Fabry patients (24%) had experienced
strokes at a median age as low as 26.5 years [36].
From the FOS Registry, the overall prevalence of ischae-
mic stroke or TIAs was 13% [37], events tending to occur
a ta ne a r l i e ra g ew i t h1 2t i m e sh i g h e rn u m b e ro fi s c h a e m i c
strokes in the male 25–44 years age group compared to what
could be expected in the general population. A signiﬁcantly
higher proportion of patients with Fabry disease, who had4 Stroke Research and Treatment
a history of cerebrovascular complications, had valvular
heart disease, left ventricular hypertrophy, arrhythmias, or
hypertension compared to those with no history of such
complications. Not surprisingly, Sims et al. [7]f o u n di nt h e
Fabry Registry that patients who had strokes were much
more likely to have reported a medical history of various
risk factors for strokes, as compared to other patients.
Compared to nonstroke patients, those who had strokes
were more likely to report TIAs (36.2% versus 5.4%),
arrhythmias (32.6% versus 12.7%), or hypertension (52.9%
versus20.5%).Furthermore, similar percentagesofmale and
femalestroke patientsreported ahistory ofTIAs.Malestroke
patients were more likely than females to have reported
a history of arrhythmias. A greater percentage of females
who had strokes reported a history of hypertension (32
of 52, 61.5%), as compared to males (41 of 86, 47.7%).
Among the two subpopulations of patients with strokes at
<30 years (all of whom had ischaemic strokes) and those
with haemorrhagic strokes, respectively, the proportion of
patients with a history of TIAs or arrhythmias was generally
similar to that observed in the overall population of Fabry
stroke patients. Finally, patients with hemorrhagic strokes
were more likely to have reported a history of hypertension
(11 of 16, 68.9%) than patients with a stroke below 30
years of age (8 of 30, 26.7%), and overall, 73 of 138
Fabry stroke patients (52.9%) had a history of hyperten-
sion.
Thus, the presence of hypertension should be a warning
sign for future strokes in young Fabry patients and be
treated vigorously with antihypertensive drugs, antiplatelet
drugs, and statins if appropriate, in order to prevent strokes.
Another warning sign is cardiac aﬀection, in particular
arrhythmia as mentioned above.
5.Prevalenceof FabryDisease amongYoung
PatientswithStroke
A screening study of 721 young German patients (age 18
to 55) who had strokes of unknown aetiology reported
that 4.9% of males and 2.4% of females had Fabry disease
[38]. Based on these ﬁndings, it was estimated that 1%
to 2% of all stroke patients within this age range could
have Fabry disease [28]. Others have suggested that this
percentage may be higher [39]o rl o w e r[ 40]. A very recent
study [41] was published from Portugal, where during
one year, all patients aged 18 to 55 years with ﬁrst-
ever stroke, who were admitted into any of 12 neurology
hospital departments, were prospectively enrolled (n =
625) and assessed for presence of a GLA mutation. Alpha-
galactosidase activity was further assayed in all patients with
GLA mutations. Four hundred ninety-three patients (mean
age, 45.4 years; 61% male) underwent genetic analyses: 364
with ischaemic stroke, 89 with intracerebral hemorrhage,
26 with subarachnoid hemorrhage, and 14 with cerebral
venous thrombosis. Twelve patients had missense GLA
mutations: 9 with ischaemic stroke, including 5 patients
with an identiﬁed cause of stroke (2 with cardiac embolism,
2 with small vessel disease, and one with other cause),
2 with intracerebral haemorrhage, and one with cerebral
venous thrombosis. Leukocyte α-galactosidase activity was
subnormal in the hemizygous males and subnormal or
lownormal in the heterozygous females. The estimated
prevalence of missense GLA mutations was thus 2.4% (95%
CI, 1.3% to 4.1%).
The StrokePreventionin Young MenStudyenrolledmen
(15 to 49 years) with ﬁrst ischaemic stroke in the Baltimore-
Washington area in 2004 to 2007 [42]. Frozen plasma
samples were assayed for α-Gal A activity, and DNA from
patients with consistently low plasma α-Gal A activities was
sequenced. In the study sample of 558 men (42% African-
American; median age 44 years), stroke was cryptogenic in
154 (40% African-American). Ten patients had low plasma
α-Gal Aactivities, butDNAsequencingidentiﬁed alterations
in the α-Gal A gene in only 2 of these patients. Their study
suggested a low yield of screening for Fabry disease in young
men with an initial ischaemic stroke regardless of aetiology.
The yield of screening in recurrent cryptogenic ischaemic
strokeinyoungadultsstillremainsunclear.Thereistherefore
aneedforalargesample sizereplicationoftheﬁndingsofthe
German study [28], which suggested a prevalence of 24.3%
for unrecognized Fabry disease among men with recurrent
cryptogenic stroke. Because Fabry disease is a treatable
conditionand thediagnosishasimplicationsforotherfamily
members, the decision to screen for Fabry disease should
be made on an individual basis. A better understanding
of the natural history of cerebrovascular manifestations of
Fabry diseasemay providevaluableinformation aboutwhich
patients may be at greatest risk for stroke. Such information
can also raise the awareness of Fabry disease within the
broader medical community and highlight the importance
of improved monitoring and management options. Despite
a low diagnostic yield, screening for GLA mutations should
probably be considered in diﬀerent types of stroke. Restrict-
ing investigation to patients with cryptogenic stroke may
underestimate the true prevalence of Fabry disease in young
patients with stroke.
6.The SpecialCaseof FemaleswithFabry
In recent years, the involvement in heterozygous females
has been more extensively documented [1, 5, 8, 9, 12, 43].
Heterozygotes for the classic phenotype of Fabry disease
c a nb ea s y m p t o m a t i ct h r o u g h o u tl i f eo rh a v ea ss e v e r e
manifestations as aﬀected males [1, 5, 8, 9, 12, 42–44]. Most
mutation-conﬁrmed heterozygotes have the corneal opaci-
ties, which are observed by slit-lamp microscopy and are a
useful diagnostic ﬁnding. About 53 to 70% of heterozygous
females will have episodic neuropathic pain as reported in
several studies [5, 8, 12, 42–44]. So the ﬁndings of pain in
the extremities, which is exacerbated by fever, exercise, and
stress, together with the typical eye changes are signiﬁcant
diagnostic ﬁndings. Other ﬁndings in Fabry heterozygotes
include sparse angiokeratoma, hypohidrosis, gastrointestinal
pain and cramping, and diarrhea. Interestingly, female Fabry
patients were shown to have a higher prevalence ofstrokes or
TIAs of 16% compared to 11% in males in the FOS registryStroke Research and Treatment 5
natural history paper [3], perhaps because fewer of them die
from renal failure.
7.Diagnosing FabryDisease
The diagnosis of Fabry disease in males is reliably made by
demonstrating the α-Gal A enzymatic deﬁciency [45]. How-
ever, in heterozygousfemales, the α-Gal A enzymatic activity
can range from very low to high normal values due to
random X-inactivation [45–47]. To accurately identify het-
erozygote, the family’s mutation must be identiﬁed. Suspect
heterozygotes with no family history of Fabry disease require
α-Gal A gene sequencing for diagnostic conﬁrmation. In a
f e wc a s e s ,t h i si sa l s od i ﬃcult if the patient does not display a
mutation on sequencing, as in case of large deletions (Feldt-
Rasmussen et al., unpublished observation). In such cases,
eyeexamination, neurologicalassessment, andkidneybiopsy
can be of importance.
8.ScreeningforFabryDisease?
The frequency of the classic phenotype has been estimated
at ∼1 in 40,000 males [1], and recent newborn screening
studies have found the incidence of classically aﬀected males
to be ∼1 in 24,620 by screening over 147,700 consecutive
newborn males in Taiwan [48, 49]a n d∼1 in 37,000
newborn males screened in Italy [50]. In the latter study, 12
male neonates had deﬁcient α-Gal A activities and speciﬁc
mutations, revealing a surprisingly high Fabry disease
incidence of one in 100 males. Of the 12 neonates with α-Gal
A deﬁciency, 11 had mutations predicting the later-onset
phenotype for an 11:1 ratio of later-onset/classic phenotypes
[50]. No similar studies have been done in females. These
ﬁgures have given rise to a discussion as to whether or not
newborn screening for Fabry males should be done due
to availability of a safe treatment option and probably an
eﬃcient one if started early in life to prevent progressive
irreversible tissue and organ damage.
While waiting for such decision, it may rather be worth-
while for clinicians to consider screening of speciﬁc patient
populations for Fabry disease [51]. These considerations
should include young people with stroke or TIAs at least
those without other known aetiology. It seems that approxi-
mately 1-2% of young stroke patients are demonstrated with
Fabry disease. The recruitment to the sifap1 (stroke in young
Fabry patients) study provides the largest prospective case
series of young stroke patients reported so far. Results are
expected to provide novel information on the prevalence
of Fabry in the population as well as characteristics of the
patients. The further analyses of results of this study will
therefore possibly add to the decision on whether or not to
screen young stroke patients for Fabry disease [52].
However, screening for Fabry disease among young
stroke patients would only be meaningful if it can be veriﬁed
that subsequent enzyme replacement or other therapy can
prevent further stroke episodes. Currently, such information
is not available from any of the published studies on
treatment eﬃcacy [53–55].
9.TreatmentOptions
As mentioned previously, ERT replacement in Fabry disease
is now a treatment option in most countries [18, 53, 54],
although a production limitation in Fabrazyme has been
known for a while, an issue which is not yet solved. One
of the drawbacks of the treatment is the fact that it needs
intravenous infusion, another one is the price. Whether or
not to start treatment early, particularly in males, to prevent
progression of organ manifestations or in some cases to
wait and see is still not agreed upon internationally. One of
the diﬃculties in obtaining proper evidence is the rarity of
the disease and the relatively short treatment and follow-up
period in the existing trials.
Apart from that, trials are going on concerning the use
of chaperone therapy, which is oral, but only eﬀective in
certain genotypes. It may, however, also prove eﬃcient in
patients with other genotypes as adjunctive therapy to ERT,
and gene therapy is another imminent therapy ready for
clinical testing [52]. In addition, it is becoming increasingly
important touse also other treatments, for example, primary
stroke prevention including lifestyle counseling and blood
pressure and lipid lowering drugs, but additionally ACE
inhibitors, angiotensin I and II receptor antagonists [13],
and ﬁnally anti-inﬂammatory agents [24]a n dv i t a m i nD
receptor agents [56]m a yp r o v ee ﬀective in slowing down
the progression of the vasculopathy and not only be used for
renal protection.
The evidence for providing ﬁrm algorithms for initiation
of therapy in males and females, respectively, is not available,
and they are therefore currently arbitrary and diverging
between countries and treatment centers.
10.Conclusion
Fewer patients than previously with Fabry disease die from
renal failure mainly due not only to a better general renal
care but also to ERT, and therefore more of them live to
experience other complications such as cardiac arrhythmias,
left ventricular hypertrophy, hypertrophic cardiomyopathy,
and stroke occurring with advancing age in both genders
[1, 5, 9, 12, 44, 57]. Thus, pediatricians, neurologists,
cardiologists, and internists should be aware of the disease
manifestations in children, adolescents, and young adults,
particularly because the earlier the diagnosis is suspected
and conﬁrmed and the earlier treatment, including ERT
is initiated, the more eﬀective is the therapy [18, 53,
56, 58]. Thus, it is important to add primary stroke
prevention including lifestyle counseling, blood pressure
and lipid-lowering drugs, and additionally ACE inhibitors,
angiotensin I and II receptor antagonists [13], in order to
slow down the progression of the vasculopathy and not
only be used for renal protection. Targeted screening for
Fabry disease among young individuals with stroke seems
to disclose unrecognized cases and may therefore very well
be recommended as routine in the future. For this to be
veriﬁed, the results of the sifap study is much awaited
[52].6 Stroke Research and Treatment
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